Bioenergetics

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Retrieved on: 
Tuesday, November 7, 2023
ACT, Bioenergetics, Microsoft Access, Science, EAP, Survival, FDA, Research, NINDS, Food, Mortality, CNM, Gold, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SALT, Engineering, ALS, Clinical trial, Medicine, Risk, Biology, Physics, MOA, Bangladesh Technical Education Board, Consultant, Columbia University, Small, Multiple sclerosis, NIH, DSM-IV codes, EAPS, Chemistry, Patient, Death, MS, National Institute of Neurological Disorders and Stroke, Cryptocurrency, Pharmaceutical industry, Stroke

In September, Clene announced long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the HEALEY ALS Platform Trial.

Key Points: 
  • In September, Clene announced long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the HEALEY ALS Platform Trial.
  • Clene expects that its resources as of September 30, 2023, will be sufficient to fund its operations into the third quarter of 2024.
  • Research and development expenses were $6.0 million for the quarter ended September 30, 2023, compared to $6.4 million for the same period in 2022.
  • General and administrative expenses were $3.7 million for the quarter ended September 30, 2023, compared to $3.6 million for the same period in 2022.

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Retrieved on: 
Thursday, September 28, 2023
Neuron, Cell death, PD, University, CNM, Bioenergetics, Neurodegenerative disease, Survival, University of South Carolina, Medicine, Research, Cell, Multiple sclerosis, SALT, Science, MS, Chemistry, Translational medicine, Small, Metabolism, Engineering, Physics, Biology, ALS, Environment, Pharmaceutical industry, Biochemistry

SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) through its wholly owned subsidiary Clene Nanomedicine Inc. (collectively, “Clene”), today announced the publication of a scientific paper describing the catalytic mechanism of action of its investigational drug CNM-Au8® in the journal Small, a top nanotechnology-focused journal at the interface of materials science, chemistry, physics, engineering, medicine, and biology. The publication, titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” is co-authored by lead investigators at the University of South Carolina and Clene.

Key Points: 
  • The publication, titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” is co-authored by lead investigators at the University of South Carolina and Clene.
  • This study demonstrates that the robust neuroprotective properties of CNM-Au8 can be attributed to its therapeutic catalytic activity.
  • When neurons were exposed to toxins that induce neuronal death, CNM-Au8 treatment promoted the survival of cells and preservation of neurite networks.
  • The remarkable promise of CNM-Au8 to address multiple different neurodegenerative diseases using this catalytic mechanism is truly exciting.”

Institute of Bioenergetics Hosts First Industry Summit - Focus on Cutting-Edge Therapies and Patient Success Stories

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Technology, Other Health, Health, Mental Health, Health Technology, Other Technology, Medical Devices, Research, Fitness & Nutrition, Science, Radiation, Depression, Life, Massey, Anxiety, Cancer, Quality of life, American Academy, Lac, Medicine, Étienne-Émile Baulieu, Regeneration, Cervical cancer, Patient, Lymph, Palliative care, Physics, Diagnosis, Pharmaceutical industry, Hospital, Bioenergetics

The Institute of Bioenergetics hosted its first bioenergetics industry summit in Park City, Utah.

Key Points: 
  • The Institute of Bioenergetics hosted its first bioenergetics industry summit in Park City, Utah.
  • At first, I was cautious of bioenergetics because it addresses the energy system of the body.
  • Participants attending the summit shared patient and customer stories about how bioenergetics has helped them on their healing journeys.
  • For more information on the Institute of Bioenergetics, its research, and upcoming events, visit www.bioenergetics.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005415/en/

Institute of Bioenergetics Hosts First Industry Summit - Focus on Cutting-Edge Therapies and Patient Success Stories

Retrieved on: 
Wednesday, May 3, 2023
Radiation, Depression, Life, Anxiety, Health, Cancer, Quality of life, American Academy, Lac, Research, Medicine, Science, Étienne-Émile Baulieu, Regeneration, Cervical cancer, Patient, Lymph, Palliative care, Physics, Diagnosis, Summit, PARK, Massey, Pharmaceutical industry, Hospital, Bioenergetics

PARK CITY, Utah, May 3, 2023 /PRNewswire/ -- The Institute of Bioenergetics hosted its first bioenergetics industry summit in Park City, Utah. The two-day event attracted more than 50 bioenergetic health leaders, researchers, doctors, and companies including Energy4Life, Ammortal, NES Health, and the American Academy of Anti-Aging Medicine. Participants discussed upcoming research, new technologies, and the future collaborations that will introduce bioenergetics to people in need.

Key Points: 
  • PARK CITY, Utah, May 3, 2023 /PRNewswire/ -- The Institute of Bioenergetics hosted its first bioenergetics industry summit in Park City, Utah.
  • At first, I was cautious of bioenergetics because it addresses the energy system of the body.
  • Participants attending the summit shared patient and customer stories about how bioenergetics has helped them on their healing journeys.
  • For more information on the Institute of Bioenergetics, its research, and upcoming events, visit www.bioenergetics.com

ACTIVE HEALTH FOODS, INC. COMPLETES “DREAM TEAM” BOARD OF DIRECTORS ADDING DRS. MILLER AND OLIVER

Retrieved on: 
Wednesday, June 29, 2022
OTC, Life, CEO, Bioidentical hormone replacement therapy, American Academy, Functional medicine, RBT, GLOBE, Bioenergetics, Association, Board of High School and Intermediate Education Uttar Pradesh, Empowerment, Founder, American Academy of Anti-Aging Medicine, Disorder, EMBA, CA, Transgender hormone therapy, Board, Physician, MD, BIO, Pharmaceutical industry, Director

Los Angeles, CA, June 29, 2022 (GLOBE NEWSWIRE) -- ACTIVE HEALTH FOODS, INC. (OTC: AHFD) announces that Dr. Philip Lee Miller, of Monterey, California, and Dr. Aubrey Oliver in Jamaica, have joined AHFDs subsidiary Bioidentical Hormones, Inc. (BIO) Board of Directors.

Key Points: 
  • Los Angeles, CA, June 29, 2022 (GLOBE NEWSWIRE) -- ACTIVE HEALTH FOODS, INC. (OTC: AHFD) announces that Dr. Philip Lee Miller, of Monterey, California, and Dr. Aubrey Oliver in Jamaica, have joined AHFDs subsidiary Bioidentical Hormones, Inc. (BIO) Board of Directors.
  • Dr. Miller has become a recognized leader in Anti-Aging integrative medicine.
  • This started with a past association with Dr. Julian Whitaker of the Whitaker Wellness Institute in Newport Beach, California.
  • He passed the first-ever Board Exams in Anti-Aging Medicine in December 1998. www.antiaging.com
    Dr. Aubrey Oliver, Functional Medicine Doctor, Naturopathic Doctor, RBT & EMBA, based in Jamaica.

ACTIVE HEALTH FOODS, INC. COMPLETES “DREAM TEAM” BOARD OF DIRECTORS ADDING DRS. AUBREY AND OLIVER

Retrieved on: 
Wednesday, June 29, 2022
OTC, Life, CEO, Bioidentical hormone replacement therapy, American Academy, Functional medicine, RBT, GLOBE, Bioenergetics, Association, Board of High School and Intermediate Education Uttar Pradesh, Empowerment, Founder, American Academy of Anti-Aging Medicine, Disorder, EMBA, CA, Transgender hormone therapy, Board, Physician, MD, BIO, Pharmaceutical industry, Director

Los Angeles, CA, June 29, 2022 (GLOBE NEWSWIRE) -- ACTIVE HEALTH FOODS, INC. (OTC: AHFD) announces that Dr. Philip Lee Miller, of Monterey, California, and Dr. Aubrey Oliver in Jamaica, have joined AHFDs subsidiary Bioidentical Hormones, Inc. (BIO) Board of Directors.

Key Points: 
  • Los Angeles, CA, June 29, 2022 (GLOBE NEWSWIRE) -- ACTIVE HEALTH FOODS, INC. (OTC: AHFD) announces that Dr. Philip Lee Miller, of Monterey, California, and Dr. Aubrey Oliver in Jamaica, have joined AHFDs subsidiary Bioidentical Hormones, Inc. (BIO) Board of Directors.
  • Dr. Miller has become a recognized leader in Anti-Aging integrative medicine.
  • This started with a past association with Dr. Julian Whitaker of the Whitaker Wellness Institute in Newport Beach, California.
  • He passed the first-ever Board Exams in Anti-Aging Medicine in December 1998. www.antiaging.com
    Dr. Aubrey Oliver, Functional Medicine Doctor, Naturopathic Doctor, RBT & EMBA, based in Jamaica.

LUCA Science Announces the Opening of a New Subsidiary in the UK and Expansion on the Collaboration With the University of Oxford on the Development of Novel Mitochondrial Therapeutics

Retrieved on: 
Wednesday, April 7, 2021
Research, Baby, Maternity, Genetics, Biotechnology, University, Pharmaceutical, Consumer, Health, Science, Education, Branches of biology, Biology, Cell biology, Mitochondria, Human pregnancy, Cellular respiration, Mitochondrion, Intrauterine growth restriction, Bioenergetics

LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.

Key Points: 
  • LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.
  • LUCA Science UK will be based in Oxford.
  • LUCA Science is a pioneer in developing a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional tissues.
  • LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent.

Auburn University's new mobile lab expands research opportunities far and wide

Retrieved on: 
Thursday, October 17, 2019
Branches of biology, Biology, Cell biology, Cellular respiration, Mitochondria, Mitochondrion, Bioenergetics

An interdisciplinary team of researchers at Auburn University is trying to determine why this is so.

Key Points: 
  • An interdisciplinary team of researchers at Auburn University is trying to determine why this is so.
  • Auburn's new mobile mitochondria labdeemed the MitoMobilewill allow researchers to travel the country to study bioenergetics without being in their campus labs.
  • The study of mitochondria involves using fresh and live tissue, so researchers only have about two hours to work with the material.
  • Hood's research also focuses on mitochondria and energybut for this particular trip, her work centered on energy used during lactation.